PLT012 / Pilatus Biosci, Elixiron Immunotherap - LARVOL DELTA

PLT012, a Humanized CD36-Blocking Antibody, Induces Durable Anti-Tumor Immunity via Immunometabolic Reprogrammig (SITC 2025) - "By enhancing effector T cell function and reducing suppressive cell populations, PLT012 overcomes ICI resistance and induces durable tumor control in both HCC and liver metastases. These findings underscore the promise of immunometabolic targeting in lipid-enriched malignancies."

Oncology • CD36 • CD8 • SCARB1

Pilatus Biosciences to Present New Preclinical Data Highlighting PLT012's Ability to Induce Durable Anti-Tumor Immunity Through Immunometabolic Reprogramming of the Tumor Microenvironment at SITC 2025 Annual Meeting (PRNewswire) - "Preclinical findings highlight PLT012's first-in-class anti-CD36 mechanism of action that reprograms immune-metabolic pathways to suppress Tregs, enhance CD8 ⁺ T-cell responses, and induce durable tumor control....'Alongside a favorable GLP toxicology profile, these data support our planned Phase I study, with first patient in (FPI) targeted for Q1 2026'."

New P1 trial • Preclinical • Solid Tumor

Pilatus Biosciences…announced the granting of its foundational patent in Europe and Australia, entitled “Methods for Modulating Regulatory T Cells and Inhibiting Tumor Growth.” (Businesswire) - "The patent covers Pilatus’ first-in-class antibody program targeting CD36, a key metabolic checkpoint expressed on regulatory T cells (Tregs) that play a critical role in suppressing anti-tumor immune responses."

Patent • Oncology

Pilatus Biosciences Announces Clinical Trial Collaboration with Roche to Evaluate PLT012 in First-in-Human Study in Hepatocellular Carcinoma (Businesswire) - "Under the terms of the agreement, Roche will provide atezolizumab (Tecentriq), its anti-PD-L1 therapy, to support Pilatus’ upcoming first-in-human Phase 1 trial evaluating PLT012 in combination with atezolizumab in patients with hepatocellular carcinoma (HCC)."

Commercial • New P1 trial • Hepatocellular Cancer

PLT012, a humanized CD36-blocking antibody, is effective for unleashing anti-tumor immunity and against liver metastasis (AACR 2025) - "Notably, ex vivo studies with human HCC samples further confirm PLT012's capacity to remodel the immune microenvironment. Taken together, these findings position PLT012 as a first-in-class immunotherapy targeting CD36, addressing critical challenges in HCC and liver metastasis treatment."

Hepatocellular Cancer • Oncology • Solid Tumor • CD36 • CD8 • SCARB1

PLT012, a Humanized CD36-Blocking Antibody, Is Effective for Unleashing Antitumor Immunity Against Liver Cancer and Liver Metastasis. (PubMed, Cancer Discov) - "Despite the success of cancer immunotherapies, like immune checkpoint inhibitors, many patients still fail to demonstrate significant responses because of metabolic constraints in tumors. PLT012 rejuvenates antitumor immunity by targeting metabolic pathways to reprogram the immune landscape of liver cancer and liver metastasis, with potential to influence future HCC immunotherapy."

Journal • Hepatocellular Cancer • Hepatology • Liver Cancer • Oncology • Solid Tumor • CD36 • SCARB1

Reprogramming the tumor microenvironment with a single punch- our journey from bench to bedside (AACR 2025) - "Notably, PLT012 also reprograms immune landscape of human HCC ex vivo. Our findings provide proof-of-concept evidence that PLT012 effectively reprograms anti-tumor immunity in HCC, positioning it as a first-in-class immunotherapy targeting CD36."

Biomarker • Tumor microenvironment • Hepatocellular Cancer • Oncology • Solid Tumor • CD36 • SCARB1

Pilatus Biosciences Publishes Preclinical Data in Cancer Discovery on PLT012 First-in-Class CD36-Targeting Antibody for Liver Cancer (Businesswire) - "Pilatus Biosciences...announced a preclinical publication in Cancer Discovery detailing the mechanism and therapeutic potential of its lead candidate, PLT012....PLT012 monotherapy drives tumor regression in both immune-inflamed and immune-excluded HCC models, including β-catenin–driven tumors resistant to checkpoint blockade. In combination with anti-PD-L1 and anti-VEGF therapies, PLT012 significantly improves tumor control and increases complete response rates. In colorectal cancer models with liver metastases, PLT012 restores responsiveness to PD-1 blockade and reprograms macrophage phenotypes."

Preclinical • Colorectal Cancer • Hepatocellular Cancer

Pilatus Biosciences to Present Research on PLT012 at AACR 2025 (PRNewswire) - "Pilatus Biosciences...will present new research on its lead candidate, PLT012, at the American Association for Cancer Research (AACR) 2025 Annual Meeting. The presentations will include an oral symposium by co-founder and Chair of the Scientific Advisory Board (SAB), Prof. Ping-Chih Ho, and a poster session by Lead Scientist, Dr. Yi-Ru Yu. These efforts highlight PLT012's potential as a novel therapeutic approach for immune-cold solid tumors. PLT012 is currently in late-stage preclinical development and progressing toward its first-in-human clinical trial."

Preclinical • Solid Tumor

Pilatus Biosciences Inc. Secures FDA Orphan Drug Designation for PLT012: A Breakthrough in Liver and Intrahepatic Bile Duct Cancer Treatment (PRNewswire) - "Pilatus Biosciences Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its leading molecule, PLT012, for treating liver and intrahepatic bile duct cancer (HCC/ICCA). Achieved in November 2024, this designation marks a crucial advancement in developing innovative therapies for patients facing these challenging cancers. Dr. Raven Lin, CEO, emphasized the company's commitment to addressing urgent medical needs, while Prof."

Orphan drug • Biliary Cancer • Cholangiocarcinoma • Hepatocellular Cancer • Oncology

PLT012: a first-in-class antibody targeting CD36, revolutionizing immunotherapy by unleashing anti-tumor immunity through metabolic reprogramming in the tumor microenvironment (SITC 2024) - "Conclusions These results demonstrate that blocking CD36-mediated metabolic alterations in Tregs and CD8+ TILs with PLT012 treatment can elicit robust tumor growth inhibition and shift the immunosuppressive nature of the TME towards an immunosupportive one in both primary HCC and liver metastases. This study further supports the potential of harnessing immunometabolic targeting in cancer immunotherapy."

Biomarker • Tumor microenvironment • Hepatocellular Cancer • Oncology • Solid Tumor • CD36 • CD8 • SCARB1

Revitalizing anti-tumor immunity through PLT012 monoclonal antibody, targeting CD36 for metabolic rewiring in the tumor microenvironment (AACR 2024) - "Taken together, these results reveal that blocking CD36-mediated metabolic alterations in Treg and CD8+ TILs with PLT012 treatment can elicit robust tumor growth inhibition and shift the immunosuppressive nature within the TME toward an immunosupportive one. This study further provides the pillar for harnessing immunometabolic targeting in cancer immunotherapy."

Biomarker • Tumor microenvironment • Oncology • CD36 • CD8 • SCARB1

PLT012, a monoclonal antibody targeting CD36, unleashes anti-tumor immunity via metabolic reprogramming in tumor microenvironment (SITC 2023) - "Conclusions These results demonstrate that blocking CD36-mediated metabolic alterations in Treg and CD8+ TILs with PLT012 treatment can elicit a robust tumor growth inhibition and shift the immunosuppressive nature within the TME toward an immunosupportive one. This study further provides the pillar for harnessing immunometabolic targeting in cancer immunotherapy."

Biomarker • Tumor microenvironment • Gastrointestinal Cancer • Hepatocellular Cancer • Melanoma • Oncology • Solid Tumor • CD36 • CD8